Search Results - "Haymana, C"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study by Atmaca, A., Demirci, I., Haymana, C., Tasci, I., Sahin, I., Cakal, E., Ata, N., Dagdelen, S., Salman, S., Emral, R., Sahin, M., Celik, O., Demir, T., Ertugrul, D., Unluturk, U., Caglayan, M., Satman, I., Sonmez, A.

    Published in Osteoporosis international (01-01-2022)
    “…Summary This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The…”
    Get full text
    Journal Article
  2. 2

    Cabergoline treatment in prolactinoma: Amelioration in obstructive and central sleep apneas by Binar, M, Karakoc, O, Haymana, C, Arslan, H

    Published in Journal of postgraduate medicine (01-01-2019)
    “…A 44-year-old male patient was admitted to the otolaryngology department with a history of progressive snoring, excessive daytime sleepiness, and reduced…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism by Sonmez, A, Haymana, C, Bolu, E, Aydogdu, A, Tapan, S, Serdar, M, Altun, B, Barcin, C, Taslipinar, A, Meric, C, Uckaya, G, Kutlu, M

    Published in European journal of endocrinology (01-05-2011)
    “…ObjectiveThe relationship between metabolic syndrome (MS) and hypogonadism has always been investigated in study groups confounded with aging, obesity or…”
    Get full text
    Journal Article
  6. 6

    Trace Element Levels in Congenital Hypogonadotrophic Hypogonadism by Aydogdu, A, C. Haymana, B. Soykut, O. Erdem, Y. Basaran, K. Baskoy, M. Dinc, A. Taslipinar, A. Sonmez, E. Bolu, O. Azal

    Published in Biological trace element research (01-05-2016)
    “…Cardiometabolic diseases are prevalent in hypogonadism. The pathophysiologic mechanism of increased cardiometabolic risk in hypogonadal patients is not clear…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Osteoprotegerin, fibroblast growth factor 23, and vitamin D3 levels in male patients with hypogonadism by Meric, C, Sonmez, A, Aydogdu, A, Tapan, S, Haymana, C, Basaran, Y, Baskoy, K, Sertoglu, E, Taslipinar, A, Bolu, E, Azal, O

    Published in Hormone and metabolic research (01-12-2014)
    “…Cardiometabolic disorders and osteoporosis are prevalent in patients with hypogonadism. Osteoprotegerin (OPG) and fibroblast growth factor-23 (FGF-23), are…”
    Get more information
    Journal Article
  9. 9

    Oxidative stress status in congenital hypogonadism: an appraisal by Haymana, C., Aydoğdu, A., Soykut, B., Erdem, O., Ibrahimov, T., Dinc, M., Meric, C., Basaran, Y., Sonmez, A., Azal, O.

    Published in Toxicology mechanisms and methods (24-07-2017)
    “…Patients with hypogonadism are at increased risk of cardiac and metabolic diseases. However, the pathogenesis of increased cardiometabolic risk in patients…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14